Fig. 2From: Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL StudyOnabotulinumtoxinA effect on (a) HIT-6 scores and (b) MIDAS scores. HIT-6 = 6-Item Headache Impact Test; MIDAS = Migraine Disability Assessment. *P < 0.001 for within-treatment-group comparison from baseline; data are observed dataBack to article page